Healthcare Equipment and Supplies
Company Overview of Sera Prognostics, Inc.
Sera Prognostics, Inc., a biotechnology company, develops diagnostic and blood tests that help physicians to predict and manage preterm birth, preeclampsia, and other pregnancy complications. Sera Prognostics, Inc. has a strategic partnership with Agilent Technologies Inc. The company was founded in 2008 and is based in Salt Lake City, Utah.
2749 East Parleys Way
Salt Lake City, UT 84109
Founded in 2008
Key Executives for Sera Prognostics, Inc.
Executive Chairman, Chief Executive Officer and President
Co-Founder, Managing Director of the Seed Fund Upstart Ventures and Director
Co-Founder and Co-Chairman of The Scientific Advisory Board
Co-Founder and Co-Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2015.
Sera Prognostics, Inc. Key Developments
Sera Prognostics, Inc. Announces Executive Changes
Feb 24 15
Sera Prognostics, Inc. announced that Arnold L. Oronsky, Ph.D., General Partner at InterWest Partners, LLC, was appointed to its board of directors. Dr. Oronsky's addition to the Sera Board occurs as the company is in the final stages of developing PreTRM, its novel proteomic predictor for preterm birth risk, prior to its commercial launch. As General Partner leading healthcare investments at InterWest Partners, Dr. Oronsky has significant experience investing in diagnostic and pharmaceutical companies. He has served on numerous boards of successful healthcare companies that address significant unmet medical needs through innovative technologies. The company also announced that Douglas Fisher, M.D., has recently resigned his position as a director on Sera's Board to join the company's management team as Chief Business Officer. Dr. Fisher has been a partner at InterWest Partners, serving on Sera's Board of Directors since November 2011. Dr. Fisher has focused on biopharmaceutical, diagnostic and medical device investments throughout his career, working in venture capital, consulting and pharmaceutical industries.
Square 1 Bank Announces Debt Facility to Sera Prognostics
Feb 11 15
Square 1 Bank announced that it has provided a $10 million debt facility to new client Sera Prognostics, Inc. Proceeds of the debt facility will provide working capital to help bolster commercialization efforts.
Sera Prognostics, Inc. Appoints Mansoor Raza Mirza to Its Board of Directors
Jan 7 15
Sera Prognostics, Inc. announced the appointment of Mansoor Raza Mirza to its Board of Directors. Dr. Mirza is Chief Oncologist at the Department of Oncology, Rigshospitalet - the Copenhagen University Hospital, Denmark. He currently serves as a director of Karyopharm Therapeutics and Metamark Genetics. Dr. Mirza chairs the Health Ministry's obligatory teaching course on non-surgical treatment of cancer for Danish doctors specializing in Clinical Oncology. He is vice-president of the Danish Gynecologic Cancer Group (DGCG) and medical director of Nordic Society of Gynecologic Oncology (NSGO).
Similar Private Companies By Industry
Recent Private Companies Transactions
November 7, 2014